Session Details
[1-MO13]JSNM Oral 13:Peptide Receptor Radionuclide Therapy (PRRT)
Thu. Nov 19, 2026 10:00 AM - 10:40 AM JST
Thu. Nov 19, 2026 1:00 AM - 1:40 AM UTC
Thu. Nov 19, 2026 1:00 AM - 1:40 AM UTC
Room 10（1F Studio 1）
Chair: Shozo Okamoto (Advanced Clinical Research Center, Fukushima Medical University), Shoko Takano (Department of nuclear medicine, Yokohama City University Hospital)
[1-MO13-01]Safety of 177Lu-DOTATATE in patients with chronic kidney disease
Kaori Fuse, Kenichiro Ogane, Kimiteru Ito (Department of Diagnostic Radiology,National Cancer Center Hospital,Tokyo,Japan)
[1-MO13-02]qSPECT/CT for Monitoring Treatment Response in a Patient with Metastatic Pheochromocytoma
Jan Vincent P. Go1, Carl Johnry J. Santos1, Deborah Ignacia D. Ona2, Rogelio Jr. N. Velasco2, Jennifer Lourdes D.L. Ng2 (1.Department of Nuclear Medicine and Theranostics, St. Luke’s Medical Center Quezon City, Philippines, 2.Department of Medicine, St. Luke’s Medical Center Quezon City, Philippines)
[1-MO13-03]Radiotoxicity after Lu-177 Dotatate therapy using gamma-H2AX fociformation in lymphocytes
Naoto Watanabe1, Kunihiko Yokoyama2, Takafumi Mochizuki3, Tetsuya Minami3, Ryou Sakasai4, Yoshikuni Iwabuchi4, Hiroshi Wakabayashi5 (1.Health Eavaluation Center, Public Central Hosptal fo Matto Ishikawa, Ishikawa, Japan, 2.Department fo Nuclear Medicine, Public Central Hosptal fo Matto Ishikawa, Ishikawa, Japan, 3.Department of Radiology, Kanazawa Medical University, Ishikawa, Japan, 4.Department of Biochemistry, Kanazawa Medical University, Ishikawa, Japan, 5.Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan)
[1-MO13-04]Tumor reduction rate of peptide receptor radionuclide therapy for neuroendocrine tumor
Noriko Takata, Naoto Kawaguchi, Masao Miyagawa, Tomohisa Okada, Fumiaki Tamai, Takuya Kitamura, Kyohei Onishi, Hayato Ishimura, Teruhito Kido (Department of Radiology, Ehime University, Ehime, Japan)